1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study.
Saved in:
| Title: | 1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study. |
|---|---|
| Authors: | Weichenthal, M.1 (AUTHOR), Gavrilova, I.2 (AUTHOR), Mangana, J.3 (AUTHOR), Leiter-Stoppke, U.4 (AUTHOR), Ellebaek, E.5 (AUTHOR), Ruhlmann, C.H.6 (AUTHOR), Ugurel-Becker, S.7 (AUTHOR), Asher, N.8 (AUTHOR), Kandolf Sekulovic, L.9 (AUTHOR), Gerasimov, A.10 (AUTHOR), Dummer, R.11 (AUTHOR), Ziogas, D.C.12 (AUTHOR), Haanen, J.B.A.G.13 (AUTHOR), Svane, I.M.5 (AUTHOR), Espinosa, E.14 (AUTHOR), Rutkowski, P.15 (AUTHOR), Mohr, P.16 (AUTHOR), Gogas, H.12 (AUTHOR), Bastholt, L.6 (AUTHOR), Schadendorf, D.17 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS963-S964. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189420041 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Weichenthal%2C+M%2E%22">Weichenthal, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gavrilova%2C+I%2E%22">Gavrilova, I.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mangana%2C+J%2E%22">Mangana, J.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leiter-Stoppke%2C+U%2E%22">Leiter-Stoppke, U.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ellebaek%2C+E%2E%22">Ellebaek, E.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ruhlmann%2C+C%2EH%2E%22">Ruhlmann, C.H.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ugurel-Becker%2C+S%2E%22">Ugurel-Becker, S.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Asher%2C+N%2E%22">Asher, N.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kandolf+Sekulovic%2C+L%2E%22">Kandolf Sekulovic, L.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gerasimov%2C+A%2E%22">Gerasimov, A.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dummer%2C+R%2E%22">Dummer, R.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ziogas%2C+D%2EC%2E%22">Ziogas, D.C.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Haanen%2C+J%2EB%2EA%2EG%2E%22">Haanen, J.B.A.G.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Svane%2C+I%2EM%2E%22">Svane, I.M.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Espinosa%2C+E%2E%22">Espinosa, E.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rutkowski%2C+P%2E%22">Rutkowski, P.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mohr%2C+P%2E%22">Mohr, P.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gogas%2C+H%2E%22">Gogas, H.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bastholt%2C+L%2E%22">Bastholt, L.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schadendorf%2C+D%2E%22">Schadendorf, D.</searchLink><relatesTo>17</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS963-S964. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189420041 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.2251 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: S963 Titles: – TitleFull: 1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Weichenthal, M. – PersonEntity: Name: NameFull: Gavrilova, I. – PersonEntity: Name: NameFull: Mangana, J. – PersonEntity: Name: NameFull: Leiter-Stoppke, U. – PersonEntity: Name: NameFull: Ellebaek, E. – PersonEntity: Name: NameFull: Ruhlmann, C.H. – PersonEntity: Name: NameFull: Ugurel-Becker, S. – PersonEntity: Name: NameFull: Asher, N. – PersonEntity: Name: NameFull: Kandolf Sekulovic, L. – PersonEntity: Name: NameFull: Gerasimov, A. – PersonEntity: Name: NameFull: Dummer, R. – PersonEntity: Name: NameFull: Ziogas, D.C. – PersonEntity: Name: NameFull: Haanen, J.B.A.G. – PersonEntity: Name: NameFull: Svane, I.M. – PersonEntity: Name: NameFull: Espinosa, E. – PersonEntity: Name: NameFull: Rutkowski, P. – PersonEntity: Name: NameFull: Mohr, P. – PersonEntity: Name: NameFull: Gogas, H. – PersonEntity: Name: NameFull: Bastholt, L. – PersonEntity: Name: NameFull: Schadendorf, D. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
